leisure time -WSS

leisure time

author：leisure time 2025-09-29 19:06:22 - browse：9

Person wearing a smart watch. -- first opinion coverage from STAT — Adobe

The Apple Watch has secured a new qualification from the Food and Drug Administration that could make the smartwatch an appealing tool for medical device companies hoping to illustrate the benefits of a common heart procedure.

Last week, the Apple Watch’s Atrial Fibrillation History feature became the first digital tool qualified under the Medical Device Development Tools (MDDT) program. Released in 2022, the feature estimates a user’s A-fib burden, or how much time they spend in atrial fibrillation, which is an irregular heart rhythm that can cause shortness of breath and fatigue, and is also linked to an increased risk of stroke.

The qualification means that FDA has determined in advance that sponsors can use the feature as a secondary endpoint in clinical trials without having to do additional work. Specifically, the Apple Watch is qualified for use as a secondary endpoint in clinical trials for cardiac ablation devices, which reduce the electrical signals that cause A-fib by scarring the heart with extreme heat or cold energy. Pulsed field ablation is the latest version of the technology, using a controlled electric field to scar tissue rather than the riskier thermal energy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Experimental asthma app from Apple and Anthem shows promise

entertainment

focus

WSS

Oprah kicked off a national conversation on obesity. Let's have it

UnitedHealth sued over use of algorithm in Medicare Advantage plans

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

NIH chief: government has fallen behind pharma on clinical trials

Experimental asthma app from Apple and Anthem shows promise

Decaf coffee targeted by food safety group under obscure FDA rule

Wikipedia

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Washington mulls new rules to avert another Change Healthcare

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

How to save PrEP access — and even expand it

Readout Newsletter: Merck, Vertex, and Viking updates

Medicare details structure of new drug price negotiation program

Cancer diagnosis changes perspective doctor, former hospital CEO

Walensky prepares to leave CDC — and Congress — behind

States should stop sabotaging methadone treatment reform

hotspot

Donor acceptance rates hint at racial, gender bias in heart transplants: study

Adam's Biotech Scorecard: A closer look at Viking Therapeutics, PDS Biotech

Ventyx halts psoriasis drug development after lackluster trial results

Donor acceptance rates hint at racial, gender bias in heart transplants: study

What health policies could hitch a ride on a spending bill?

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

entertainment

leisure time

focus

focus